Topical HPV treatment shows promise in early-stage readout

Having raised enough capital to sustain the company through 2025, Antiva reached a critical value inflection point Wednesday with positive top-line data for its topical HPV therapy.

In a Phase Ib/II study, 3 mg cumulative dosing of ABI-2280 led to a 46% rate of negativity for cervical high-risk HPV (hrHVP) infection at 12 weeks, compared with 16% for placebo, among women who had persistent hrHPV lasting more than 12 months. The less frequently dosed 5 mg cohort had a numerical, but not statistically significant, advantage over placebo, which the company said would guide its dosing strategy for Phase IIb studies...